PDS Biotechnology PDSB Stock
PDS Biotechnology Price Chart
PDS Biotechnology PDSB Financial and Trading Overview
| PDS Biotechnology stock price | 3.39 USD |
| Previous Close | 5.98 USD |
| Open | 5.91 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 5.75 - 6.35 USD |
| 52 Week Range | 2.89 - 13.65 USD |
| Volume | 1.19M USD |
| Avg. Volume | 758.77K USD |
| Market Cap | 191.72M USD |
| Beta (5Y Monthly) | 1.847405 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.29 USD |
PDSB Valuation Measures
| Enterprise Value | 142.48M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.1744967 |
| PEG Ratio (5 yr expected) | -0.05 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.659176 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.348 |
Trading Information
PDS Biotechnology Stock Price History
| Beta (5Y Monthly) | 1.847405 |
| 52-Week Change | 85.67% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 13.65 USD |
| 52 Week Low | 2.89 USD |
| 50-Day Moving Average | 6.77 USD |
| 200-Day Moving Average | 6.93 USD |
PDSB Share Statistics
| Avg. Volume (3 month) | 758.77K USD |
| Avg. Daily Volume (10-Days) | 2.36M USD |
| Shares Outstanding | 30.82M |
| Float | 29.44M |
| Short Ratio | 4.68 |
| % Held by Insiders | 4.48% |
| % Held by Institutions | 22.40% |
| Shares Short | 2.68M |
| Short % of Float | 9.16% |
| Short % of Shares Outstanding | 8.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -41.13% |
| Return on Equity (ttm) | -86.78% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -42552508 USD |
| Net Income Avi to Common (ttm) | -42041252 USD |
| Diluted EPS (ttm) | -1.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 65.2M USD |
| Total Cash Per Share (mrq) | 2.12 USD |
| Total Debt (mrq) | 23.51M USD |
| Total Debt/Equity (mrq) | 57.32 USD |
| Current Ratio (mrq) | 16.46 |
| Book Value Per Share (mrq) | 1.335 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -32529332 USD |
| Levered Free Cash Flow (ttm) | -23246652 USD |
Profile of PDS Biotechnology
| Country | United States |
| State | NJ |
| City | Florham Park |
| Address | 25B Vreeland Road |
| ZIP | 07932 |
| Phone | 800 208 3343 |
| Website | https://www.pdsbiotech.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 26 |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Q&A For PDS Biotechnology Stock
What is a current PDSB stock price?
PDS Biotechnology PDSB stock price today per share is 3.39 USD.
How to purchase PDS Biotechnology stock?
You can buy PDSB shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PDS Biotechnology?
The stock symbol or ticker of PDS Biotechnology is PDSB.
Which industry does the PDS Biotechnology company belong to?
The PDS Biotechnology industry is Biotechnology.
How many shares does PDS Biotechnology have in circulation?
The max supply of PDS Biotechnology shares is 34.52M.
What is PDS Biotechnology Price to Earnings Ratio (PE Ratio)?
PDS Biotechnology PE Ratio is now.
What was PDS Biotechnology earnings per share over the trailing 12 months (TTM)?
PDS Biotechnology EPS is -1.39 USD over the trailing 12 months.
Which sector does the PDS Biotechnology company belong to?
The PDS Biotechnology sector is Healthcare.
PDS Biotechnology PDSB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
- {{ link.label }} {{link}}